cas 910463 68 2 online manufacturer Manufacturer

Sermaglutide CAS 910463-68-2 Molecular Weight 4113.64 On September 20, 2019, the FDA officially approved the marketing application for Sommarutide, which is used in combination with diet and exercise to improve blood sugar control in patients with type 2 diabetes. Sommarutide is a human GLP-1 analogue with high albumin affinity and a long half-life. It can be administered once a week to stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner.

The biological activity of peptides is extensive and important, and they can act on the endocrine system, digestive system, cardiovascular system and so on. Although the history of peptides as pharmaceuticals is relatively short, it develops rapidly and has become a hot spot in the market. In the past decades, the number of peptide medications entering the clinical stage has been increasing, such as Semaglutide, Vasopressin, Edotreotide, Thymopentin, etc. With the rapid